Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Novo Nordisk A/S (NYSE: NVO) shares jumped nearly 8% in after-hours trading on Monday following a major regulatory milestone: the U.S. Food and Drug Administration approved the company’s Wegovy pill, making it the first oral GLP-1 receptor agonist authorized for chronic weight management. The approval marks a significant expansion of Novo Nordisk’s obesity treatment portfolio and could reshape the competitive landscape of the global weight loss market.
The newly approved Wegovy pill contains once-daily oral semaglutide 25 mg and is designed for adults with obesity or overweight who have at least one weight-related comorbidity. Clinical data supporting the FDA decision came primarily from the OASIS 4 trial, a 64-week, randomized, placebo-controlled study involving 307 participants. Results showed a mean weight loss of 16.6% among patients who adhered to treatment, a level comparable to the weight reduction achieved with the injectable Wegovy 2.4 mg formulation. Notably, about one in three participants achieved weight loss of 20% or more during the trial.
Beyond weight reduction, the FDA approval also includes indications to help patients maintain long-term weight loss and reduce the risk of major adverse cardiovascular events. The safety and tolerability profile of the Wegovy pill was consistent with previous semaglutide trials, reinforcing confidence in its clinical use. Gastrointestinal side effects observed were in line with those already known for GLP-1 receptor agonists.
“The pill is here. With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Mike Doustdar, president and CEO of Novo Nordisk. His comments highlight the potential appeal of an oral alternative for patients who prefer not to use injections.
Novo Nordisk plans to launch the Wegovy pill in the United States in early January 2026. The company has also submitted regulatory applications to the European Medicines Agency and other global authorities in the second half of 2025. The broader OASIS clinical development program included four trials enrolling around 1,300 adults, underscoring the company’s long-term commitment to expanding access to effective obesity treatments worldwide.
